Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Ther ; 27(8): 1495-1506, 2019 08 07.
Article in English | MEDLINE | ID: mdl-31208914

ABSTRACT

Neuronopathic glycosphingolipidoses are a sub-group of lysosomal storage disorders for which there are presently no effective therapies. Here, we evaluated the potential of substrate reduction therapy (SRT) using an inhibitor of glucosylceramide synthase (GCS) to decrease the synthesis of glucosylceramide (GL1) and related glycosphingolipids. The substrates that accumulate in Sandhoff disease (e.g., ganglioside GM2 and its nonacylated derivative, lyso-GM2) are distal to the drug target, GCS. Treatment of Sandhoff mice with a GCS inhibitor that has demonstrated CNS access (Genz-682452) reduced the accumulation of GL1 and GM2, as well as a variety of disease-associated substrates in the liver and brain. Concomitant with these effects was a significant decrease in the expression of CD68 and glycoprotein non-metastatic melanoma B protein (Gpnmb) in the brain, indicating a reduction in microgliosis in the treated mice. Moreover, using in vivo imaging, we showed that the monocytic biomarker translocator protein (TSPO), which was elevated in Sandhoff mice, was normalized following Genz-682452 treatment. These positive effects translated in turn into a delay (∼28 days) in loss of motor function and coordination, as measured by rotarod latency, and a significant increase in longevity (∼17.5%). Together, these results support the development of SRT for the treatment of gangliosidoses, particularly in patients with residual enzyme activity.


Subject(s)
Carbamates/pharmacology , Enzyme Inhibitors/pharmacology , Glucosyltransferases/antagonists & inhibitors , Quinuclidines/pharmacology , Sandhoff Disease/enzymology , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Disease Models, Animal , Female , Glucosyltransferases/genetics , Glucosyltransferases/metabolism , Ligands , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mass Spectrometry , Mice , Mice, Knockout , Molecular Imaging , Receptors, GABA/metabolism , Sandhoff Disease/diagnosis , Sandhoff Disease/genetics , Sandhoff Disease/therapy , Sphingolipids/metabolism , beta-Hexosaminidase beta Chain/genetics , beta-Hexosaminidase beta Chain/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...